A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)

NCT03537014 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Posttraumatic Stress Disorder

Interventions

BEHAVIORAL: Therapy
DRUG: midomafetamine HCl
DRUG: Placebo

Sponsor

Resilient Pharmaceuticals